Novaccess Global INC 10-K annual reports

NovAccess Global Inc., a biopharmaceutical company, reported a significant net loss and a growing working capital deficit for fiscal year 2024, highlighting severe liquidity challenges despite progress in immunotherapy development.

NovAccess Global has filed an amendment to its annual report to correct a minor error in its internal control over financial reporting disclosure.

NovAccess Global Inc.'s 10-K filing details its focus on developing novel immunotherapies for brain tumors, its financial challenges, and a recent significant funding agreement.